Elutex

Elu Therapeutics (EluTx) is a clinical-stage biotechnology company developing a novel class of targeted therapies for cancer using its proprietary C-Dot (Cornell Dot) platform. The company's "Elu-S" technology utilizes ultra-small, silica-based nanoparticles that are engineered to deliver high-potency payloads, such as cytotoxic drugs, directly to tumor cells with high precision. This platform is designed to provide superior tumor penetration and a wider therapeutic window compared to traditional antibody-drug conjugates (ADCs). EluTx's lead candidate, ELU-001, is currently in Phase 1/2 clinical trials for the treatment of folate receptor alpha (FRα)-overexpressing cancers, including ovarian and endometrial malignancies. The company is also advancing a pipeline of additional C-Dot conjugates targeting various solid tumors and exploring applications in radiopharmaceuticals.